COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01403064
Recruitment Status : Terminated (due to lack of efficacy)
First Posted : July 27, 2011
Last Update Posted : July 9, 2020
Information provided by (Responsible Party):
CSL Behring

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy

Condition or disease Intervention/treatment Phase
Oral Mucositis Biological: ALD518 Drug: 0.9% saline Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy
Study Start Date : July 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open Label ALD518 Biological: ALD518

Experimental: ALD518 Dose 1 Biological: ALD518

Experimental: ALD518 Dose 2 Biological: ALD518

Placebo Comparator: Placebo Drug: 0.9% saline
IV Infusion

Primary Outcome Measures :
  1. Safety and tolerability of ALD518, including incidence of adverse events, serious adverse events and clinically significant laboratory abnormalities [ Time Frame: Participants will be followed for the duration of the trial, an expected average of 12 months ]
  2. Clinically assessed ulcerative OM (Who Grade ≥ 2) at a cumulative radiation dose of 55 Gy [ Time Frame: The average time of this assessment will be 5-7 weeks after the initiation of RT ]

Secondary Outcome Measures :
  1. Secondary efficacy endpoint of OM assessments [ Time Frame: Measured from onset of OM through Week 4 Post-RT ]
    Ulcerative (WHO Grade ≥ 2) and severe (WHO Grade ≥ 3) OM at cumulative doses of 35 Gy, 45 Gy, 55 Gy and 65 Gy; Duration of ulcerative and severe OM, Time of onset of ulcerative and severe OM

  2. Pharmacokinetics of ALD518 in plasma [ Time Frame: Measured at Baseline, Week 2, Week 4, Last Day of RT and Week 4 Post-RT ]
  3. Impact of ALD518 on Patient-reported Outcomes as measured by the OMDQ, FACT-HN, and FACIT-fatigue scale [ Time Frame: Begins at baseline and is measured at least weekly though WEek 4 Post-RT ]
  4. C-reactive protein serum concentrations [ Time Frame: Measured at intervals from Screening visit through Week 4 Post-RT ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have recently diagnosed (< than 6 months prior to screening visit date), pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as first-line treatment; subjects with a history of surgical management (approximately 4-6 weeks before RT with sufficient time for post-surgical healing) are eligible
  • Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy.
  • Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin regimen administered weekly (100 mg/m2)
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • CRP < 80 mg/L
  • Have adequate hematopoietic, hepatic, and renal function at the screening visit

Exclusion Criteria:

  • Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor
  • Metastatic disease (M1) Stage IV C
  • Any prior history of head and neck cancer
  • Prior radiation to the head and neck
  • Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; or anticipation of need for a major surgical procedure during the clinical trial
  • Active infectious disease, excluding oral candidiasis
  • Have OM at the screening visit
  • Have a history of hypersensitivity to monoclonal antibody

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01403064

Show Show 31 study locations
Sponsors and Collaborators
CSL Behring
Layout table for investigator information
Study Director: Jeffrey Smith, MD FRCP Alder Biopharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: CSL Behring Identifier: NCT01403064    
Other Study ID Numbers: ALD518-CLIN-009
First Posted: July 27, 2011    Key Record Dates
Last Update Posted: July 9, 2020
Last Verified: April 2018
Keywords provided by CSL Behring:
Oral mucositis; head and neck cancer; chemotherapy; radiotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases